anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Fibrate and statin monotherapy increase the risk of myositis or myopathy, and have been associated with rhabdomyolysis. Data from observational studies suggest that the risk for rhabdomyolysis is increased when fibrates are co-administered with a statin (with a significantly higher rate observed for gemfibrozil). Refer to the respective statin labeling for important drug-drug interactions that increase statin levels and could increase this risk. The risk for serious muscle toxicity appears to be increased in elderly patients and in patients with diabetes, renal failure, or hypothyroidism.

Myalgia was reported in 3.3% of patients treated with Trilipix monotherapy and 3.1% to 3.5% of patients treated with Trilipix co-administered with statins compared to 4.7% to 6.1% of patients treated with statin monotherapy. Increases in creatine phosphokinase (CPK) to > 5 times upper limit of normal occurred in no patients treated with Trilipix monotherapy and 0.2% to 1.2% of patients treated with Trilipix co-administered with statins compared to 0.4% to 1.3% of patients treated with statin monotherapy.

Myopathy should be considered in any patient with diffuse myalgias, muscle tenderness or weakness, and/or marked elevations of CPK levels. Patients should promptly report unexplained muscle pain, tenderness or weakness, particularly if accompanied by malaise or fever. CPK levels should be assessed in patients reporting these symptoms, and Trilipix and statin therapy should be discontinued if markedly elevated CPK levels occur or myopathy or myositis is diagnosed.
UNLABELLED: OBJECTIVE: Identifying reliable predictors of mortality in end-stage renal disease patients is crucial for patient outcomes. Aortic knob width is a radiographic parameter used to assess cardiovascular diseases and atherosclerosis. This study investigated the association between aortic knob width and mortality in hemodialysis patients. PATIENTS AND METHODS: The study included data collected between 2007 and 2022 from 103 patients aged between 18 and 85 who had been undergoing hemodialysis treatment for at least one year. Patients were divided into two groups: survivors and deceased. The aortic knob width was measured using a posterior-anterior chest radiograph after midweek hemodialysis. The relationship between aortic knob width and mortality was investigated. RESULTS: Deceased patients had significantly larger aortic knob widths compared with survivors. The deceased group's hemodialysis (HD) duration was shorter, median age was older, Kt/V, hemoglobin, and albumin levels were lower, and the frequency of patients with hypertension, diabetes, and aortic wall calcification was higher. Aortic knob width greater than 37.98 mm was identified as a predictor of mortality in hemodialysis patients. Survival rates for aortic knob width <37.98 mm are 98.1% for 1 year and 64.9% for 15 years. For aortic knob width larger than 37.98 mm, survival rates are 88% for three years, 68% for five years, 45.2% for ten years, and 25% for fifteen years. The most important risk factors for increased aortic knob width were age, male sex, aortic calcification, and hypertension. CONCLUSIONS: Age, male gender, aortic calcification, and hypertension are the primary risk factors for increased aortic knob width in hemodialysis patients. Aortic knob width greater than 37.98 mm, which can be measured simply and rapidly using posterior-anterior chest radiography, may be a predictor of mortality.
GRAPHICAL ABSTRACT: https://www.europeanreview.org/wp/wp-content/uploads/Graphical-Abstract-10.jpg.
<P>PROBLEM TO BE SOLVED: To provide a herbal medicinal composition for curing a wound difficult to cure caused by a bedsore or an injury and a pasty preparation for external application.  <P>SOLUTION: The herbal medicinal composition for curing an external wound and a bedsore contains herbal medicinal materials such as dried ginger root, dried aconiti tuber or dried aconiti tuber after soaked in bittern, and cinnamon bark as the effective ingredients. A more preferable preparation further contains nutlets of Z. piperitum DC, nutlets of Evodia rutaecarpa, roots of Chinese peony, bark of Magnolia obovata, frankincense, myrrh, and gambier. Another preferable preparation of the herbal medicine contains an extract from the freeze-dried mycelium of enoki mushroom in the preparation described above. The herbal medicine is an ointment obtained by pulverizing the medicinal materials of this formulation, and adding a fat (e.g. lard) to and mixing it with the pulverized materials to make them pasty.  <P>COPYRIGHT: (C)2010,JPO&INPIT
The invention encompasses pharmaceutical compositions comprising an anti-interferon gamma antibody and methods of formulating antibodies. The invention addresses the problem of providing a stable pharmaceutical composition for an anti-interferon gamma antibody. The heavy and/or light chain variable region of the antibody can comprise a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO:34, a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO:35, a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO:36 or SEQ ID NO:37, a light chain CDR1 comprising the amino acid sequence of SEQ ID NO:38, SEQ ID NO:39, or SEQ ID NO:40, a light chain CDR2 comprising the amino acid sequence of SEQ ID NO:41 or SEQ ID NO:42, and a light chain CDR3 comprising the amino acid sequence of SEQ ID NO:43 or SEQ ID NO:44. The antibody can comprise an N-glycan site in a heavy and/or light chain variable region, and a preparation of the antibody can contain at least three different isoforms of the antibody. A pharmaceutical composition can be at a pH of from about 5.5 to 6.5 or from about 5.7 to 6.5. The pharmaceutical compositions may comprise a buffering agent and, optionally, a sugar and/or a salt.
In this trial, 32 healthy subjects are planned to be enrolled in fasting. According to the randomization table, subjects will be randomly assigned to one of the two groups (Group A: TRTR, Group B: RTRT). The washout period (dosing interval) between doses will be at least 5 days. After fasting for at least 10 hours, subjects were given either the test formulation (T) Entacapone, Levodopa and Carbidopa Tablets (II) or the reference formulation (R) Entacapone,Levodopa and Carbidopa Tablets (II) in 240 milliliter (mL) of warm water. 1 tablet 100mg/25mg/200mg orally per cycle.
OBJECTIVE: Cancer pain is a common distressing symptom. Numerical Pain Scales (NPS) assess pain but lack information about function and quality of life. This feasibility study assesses the use of triaxial accelerometers to measure function as an outcome measure in pain studies in advanced cancer.
METHODS: Advanced cancer participants were recruited from two palliative care services, with an average pain score of ≥3 on NPS. ActiGraph wGT3X-BT Accelerometers were worn for 1 week on the wrist. Patients recorded daily pain scores, Edmonton Symptom Assessment Scale (ESAS) scores, and their daily opioid use.
RESULTS: 24 participants were recruited. A total of 142 days of accelerometer data was collected (5.9 days/participant). The average daily step count was 5723.7. The average acceleration was 14.4 milligravity units/day. An average of 93 min/day total activity across all intensities was recorded. No correlation was seen between acceleration or average daily minutes in activity and total daily oral morphine equivalent, ESAS, 'average pain' score or 'worst pain' scores using spearman's correlation coefficients. Overall, participants were satisfied with the study.
CONCLUSIONS: Accelerometers are a feasible method to measure activity as an outcome measure in advanced cancer. Further study is required to assess the impact of pain management strategies on function.
Diabetes insipidus is a condition characterised by a large volume of diluted urine production and increased thirst. In this case report, a 49-year-old gentleman presented with 3 months of polyuria and polydipsia. He had a repeated history of hypokalemia. On the evaluation of polyuria and polydipsia, he was diagnosed with partial nephrogenic diabetes insipidus based on his inability to concentrate urine after a water deprivation test and his less than 50% response to exogenous desmopressin. On the evaluation of recurrent hypokalemia, the investigation reports met biochemical criteria for the diagnosis of Gitelman syndrome. He was encouraged to increase his fluid intake as required, and potassium chloride supplementation relieved his symptoms. This case report demonstrates the reversibility of nephrogenic diabetes insipidus with a correction of hypokalemia.
BACKGROUND: We recently developed a preliminary predictive model identifying clinical and radiologic factors associated with the need for surgery following blunt abdominal trauma (BAT) in children. Our aim in this study was to further validate the factors in this predictive model in a multi-institutional study.
METHODS: A retrospective chart review of pediatric patients from five pediatric trauma centers who experienced BAT between 2011 and 2020 was performed. Patients under 18 years of age who had BAT and computed tomography (CT) abdomen imaging were included. Children with evidence of pneumoperitoneum, and hemodynamic instability were excluded. Fisher's exact test was used for statistical analysis of the association between the following risk factors and need for laparotomy: abdominal wall bruising (AWB), abdominal pain/tenderness (APT), thoracolumbar fracture (TLF), presence of free fluid (FF), presence of solid organ injury (SOI). A predictive logistic regression model was then estimated employing these factors.
FINDINGS: Seven hundred thirty-four patients were identified in this multi-institutional dataset with BAT and abdominal CT imaging, and 726 were included. Of those, 59 underwent surgical intervention (8.8%). Univariate analysis of association between the studied factors and need for surgical management showed that the presence of TLF (p < 0.01), APT (p < 0.01), FF (p < 0.01), and SOI (p < 0.01) were significantly associated. A predictive model was created using the 5 factors resulting in an area under the curve (AUC) of 0.80. For the motor vehicle collisions (MVC) group, only FF, SOI, and TLF are significantly associated with the need for surgical intervention. The AUC for the MVC group was 0.87.
CONCLUSIONS: A clinical and radiologic prediction rule was validated using a large multi-institutional dataset of pediatric BAT patients, demonstrating a high degree of accuracy in identifying children who underwent surgery. FF, SOI, and TLF are the most important factors associated with the need for surgical intervention.
LEVEL OF EVIDENCE: Level III.
The invention relates to a respiratory system disease treating therapeutic, refined by medicine materials with fixed ingredients and proportions. The respiratory can be produced into fluidextract, pill, tablet, capsules, granule, suppository, syrup, oral liquid or dropping pill and is provided with efficacies of anti-bacteria, anti-inflammatory, relieving cough and asthma and expelling phlegm. Theresults of clinical study of 413 cases of syndromes of lung hurt caused by dryness (acute tracheitis and bronchitis) indicate that the clinical therapeutic effect of treatment group of invention embodiment comprises 62 cases of healing, 160 cases of positive effect, 65 cases of effect and 22 cases of no effect; the general efficiency is 92.88%; the clinical therapeutic effect of comparison groupof fluidextract for nourishing and clearing lung-heat comprises 14 cases of healing, 46 cases of positive effect, 30 cases of effect and 14 cases of no effect; and the general efficiency is 86.54%. After compare the therapeutic effects between the treatment group and the comparison group and adopt statistics to process data, the result is P is bigger 0.05, which indicates significant difference. Compared with main marketed products, the treating therapeutic is more effective at the aspects of relieving cough, reducing phlegm, relieving asthma and anti-acute and chronic inflammations. The treating therapeutic provides a safe and nontoxic good medicine, which can relieve cough, reduce phlegm, relieve asthma and reduce inflammation.
BACKGROUND: Outcomes and safety of "mix and match" in total hip arthroplasty (THA) using universal head-neck adapters (UHNA) are a matter of ongoing discussion and concern due to legal affairs. This study aimed at analyzing the "mix and match" use of UHNA and evaluating complication and reoperation rates, possible risk factors, and the implant's survival.
METHODS: A total of 306 patients treated with THA (94.1% revisions) using a UHNA at our institution between 2006 and 2022 were identified and included. Diagnoses, comorbidities, implants, and UHNA specifications were retrospectively recorded. Outcomes, complications, and survival analyses were evaluated, taking into account various possible risk factors.
RESULTS: There were 19.9% of the 306 included cases (58.5% women; median age 74 years; median follow-up 57 months) that had at least 1 complication. There were 43 patients (14.1%) who had to receive ≥1 rerevision surgery. The most common complication was postoperative recurrent dislocation (n = 27, 8.8%). There was one case of a prosthetic stem-neck fracture that was registered. Statistically significant risk factors for postoperative recurrent dislocations and postoperative aseptic loosening were, respectively, dislocation as an indication for UHNA implantation (P < .001) and oversized neck lengths (≥2XL; P = .004). The overall revision-free survival was 92% after 1 year and 82% at ten years. Statistically significant better survival rates were registered in patients ≥60 years old, who had fewer comorbidities (<2), and normal neck lengths (S to XL).
CONCLUSIONS: The results of this study underline the overall safety of UHNA use in THA through "mix and match." Only one case of a stem-neck fracture was identified. The highlighted risk factors for failure must be kept in mind during the decision-making process with patients.
Methods for manufacturing drug delivery systems are provided. The drug delivery systems may include a substrate coated with at least one polymer and at least one active compound. The substrate may include yarns, yarn precursors, threads, filaments, fibers, and/or other suitable substrates. The methods may include applying a solution including a monomer and an active compound on the substrate. The methods may also include exposing the solution and the substrate to UV light to initiate polymerization of the solution. The substrate is further configured into a reversibly removable patch or section to deliver active compounds to a user. The garments, patches, and sections are configured to provide an amount of active even after repeated uses, wears, applications, and/or launderings and further provide for replacement.
The Parkinson's Disease (PD) is a chronic neurodegenerative condition characterized by motor symptoms such as tremors, rigidity, and bradykinesia, which can significantly impact various aspects of daily life. Among these aspects, pain is a prominent element. Despite the widespread use of therapies aimed at improving symptoms and quality of life, effective pain management is essential to enhance the quality of life of individuals affected by this disease. However, a detailed understanding of the factors associated with pain in PD is still evolving. In this study, we examined the disability caused by pain and the pain experienced by PD patients using two validated questionnaires, namely the Parkinson's Disease Questionnaire (PDQ) and the King's Parkinson's Disease Pain Questionnaire (KPPQ). Customized questions were also included to further explore the pain experience and management strategies adopted by PD patients. Through statistical analysis, we explored the relationships between questionnaire scores, socio-demographic data, and other relevant variables. Additionally, generative Artificial Intelligence (AI) was employed to gain a deeper understanding of patient responses. The results indicate the extent and impact of pain in PD and provide valuable insights for more targeted and personalized management. This study lays the foundation for future research and the development of interventions aimed at improving the quality of life for individuals affected by this condition.
Athletes in this cohort serve as control subjects participating in Division 1 Athletics at the University of Wyoming. They will be enrolled once they meet eligibility. Upon enrollment, all athletes will have an initial BrainPulse recording. Once a subject from this cohort sustains an injury, they crossover to Cohort II. Also, a matched control for every concussed subject will be selected from Cohort Ia.
Older adults are more affected by cognitive impairments due to TBI as compared to younger adults. In addition, older adults are at a much higher risk for sedentary behavior. To address this, we intend to test the effect of two behavioral interventions on walking participation of older adults with a history of mild or moderate TBI. Participants will be randomized to either the planning, reminders, and micro-incentives group or to the health education tips group which are delivered over the phone and available virtually. We will give each participant a Fit Bit for the duration of the study, and we will use it to track their walking. Our primary aim is to see if there is a difference in the activity levels between the groups. Our secondary aim is to see if the MRI data we collect shows intra-brain connections correlate with physical activity.

Our study is a 12-week two arm pilot randomized control trial-comparing two behavioral interventions. In one group, participants will have a weekly phone call with lab staff planning 5 days during each week that they plan on having a 30-minute walk. On the days of the walk, participants will receive either a text or an email, of their choice, reminding them of the planned walk. Participants will earn points for each planned walk completed; these can then be redeemed for a monetary reward at the end of the study. The other group will have a weekly phone call with lab staff where a health education tip is shared. Participants will also be provided a study FitBit where they will wear it during the times of the day when they are active.

Following recruitment and informed consent, each participant will come into ISEC for their baseline assessment. During this assessment they will fill out questionnaires on their health history to include: Physical Activity Readiness Questionnaire, Ohio state university TBI Questionnaire, PROMIS global health and NeuroQoL Questionnaires, Mediterranean diet adherence, International Physical Activity Questionnaire, Pittsburgh Sleep Quality Index, GAD-7, PHQ-9, BREQ-3 Physical Exercise Motivation, and the Physical Exercise Self Efficacy Questionnaire. Next, the participant will be asked to complete a battery of cognitive tests including: Digital and Paper Trail Making, Hopkins Verbal Learning Test, Letter and Category Fluency Test, and a mini mental status exam. This data will all be recorded via redcap. Next, the participant will undergo an MRI. This will take about an hour and the data will be uploaded to the Northeastern Cluster. Upon completion of the baseline session, each participant will be given a Fit Bit and assigned to the health education group or the planning, reminders, and micro-incentives group. Over the next 12 weeks, study staff will have access to the FitBit data collected and complete weekly calls with the participants, the content varying based on which group the participant is in. The final steps for the participants is their remote post testing where they will complete the same cognitive tasks and questionnaires as in their baseline assessment.
Risk Summary   
There are no available data on collagenase clostridium histolyticum use in pregnant women to evaluate for a drug- associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. Following subcutaneous injection, the systemic concentrations for QWO were below the bioanalytical assay limit of quantification [see Clinical Pharmacology (12.3)].

In animal reproduction studies, intravenous administration of collagenase clostridium histolyticum to pregnant rats during organogenesis at doses up to 0.13 mg/rat (43 × human equivalent dose [HED] on a mg/kg basis) revealed no evidence of harm to the fetus.

The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the US general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively.
Participants receive BL-M05D1 as intravenous infusion for the first cycle (3 weeks). Participants with clinical benefit could receive additional treatment for more cycles. The administration will be terminated because of disease progression or intolerable toxicity occurring or other reasons.
Approximately 40,000 new cases of head and neck cancer are diagnosed annually in the United States 1. Squamous cell carcinomas account for more than 90% of head and neck cancer cases. Patients with squamous cell carcinoma of the head and neck (HNSCC) usually present with locoregionally advanced disease. Initial presentation with distant metastasis may occur in about 10% of all patients. However, recurrence of disease either in local or distant sites after potentially curative treatment with surgery, radiation, and/or chemotherapy occurs in more than 50% of patients. Therefore, the majority of patients with HNSCC develop recurrent or metastatic disease during the course of their illness. These patients have a dismal prognosis with a median survival of 6-9 months 2-4.

Active single agents in head and neck squamous cell carcinoma include methotrexate, bleomycin, cisplatin, carboplatin, 5-FU, paclitaxel, docetaxel, and CPT-11. A small randomized study showed that cisplatin monotherapy prolongs survival compared with best supportive care 5. Response rates for single agents range between 10-40% 2, 4, 6, 7. Combination chemotherapy with platinum agents, in spite of achieving higher response rates (about 30% in phase III trials), has not been shown to produce a survival benefit compared to single agents in randomized comparisons in recurrent/metastatic head and neck cancer 2, 4.
Subjects will be submitted to a bi-weekly, 50-minute session of the standard sequence of Pilates exercises (traditional sequence of the contemporary / classical method) for twelve weeks. The exercises will be performed using the same equipment used in the intervention group, but following the dorsal decubitus, sedestation and orthostasis, in a time-balanced distribution in each session.